STANDARD BIOTOOLS INC.
Close on Oct 19, 2026
- Market cap
- $251.45M
- P/E (TTM)
- 2.9
- Dividend yield
- –
Earnings
Next report expected Nov 3, 2026, after market close (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 5, 2026 | After market close | $20.10M | – | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 5, 2026 | After market close | $21.10M | $0.33 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Feb 24, 2026 | After market close | $23.80M | $0.05 | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 4, 2025 | After market close | $46.20M | – | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 11, 2025 | After market close | $21.80M | – | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 6, 2025 | After market close | $40.80M | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Feb 26, 2025 | After market close | $46.70M | $-0.09 | – |
| Q3 FY2024 Ended Sep 30, 2024 | Oct 30, 2024 | After market close | $45.00M | $-0.07 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Jul 31, 2024 | After market close | $37.20M | $-0.12 | – |
| Q4 FY2023 Ended Dec 31, 2023 | Feb 28, 2024 | After market close | $28.19M | $-0.25 | – |
| Q3 FY2023 Ended Sep 30, 2023 | Nov 7, 2023 | After market close | $25.40M | $-0.27 | – |
Company guidance
Outlook given with results on May 5, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| revenue | fiscal year 2026 | $80.00M to $85.00M | New |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Standard Biotools filed with the SEC
Standard BioTools Announces Agreement to Sell Microfluidics Business to ARCHIMED
Regulation FD disclosure · EX-99.1 to Form 8-K
Standard BioTools Provides Update on Sale of Mass Cytometry Business
Material agreement · Agreement terminated · Regulation FD disclosure · EX-99.1 to Form 8-K
Standard BioTools Reports Second Quarter 2026 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Standard BioTools Announces Sale of Mass Cytometry Business and Illumina’s Buyout of Contingent Payments to Advance Merger with Treeline Biosciences
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Standard BioTools and Treeline Biosciences Announce
Material agreement · Unregistered share sale · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Thank you for joining the Standard BioTools and Treeline Biosciences merger
Material agreement · Unregistered share sale · Executive or director change · Regulation FD disclosure · EX-99.2 to Form 8-K
Transaction and Company Overview June 2026
Material agreement · Unregistered share sale · Executive or director change · Regulation FD disclosure · EX-99.3 to Form 8-K
Standard BioTools Reports First Quarter 2026 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Standard BioTools Reports Fourth Quarter and Full Year 2025 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Completes Sale of SomaLogic to Illumina
Acquisition or disposition completed · Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Standard BioTools Announces Preliminary Fourth Quarter and Full Year 2025 Revenue
Results of operations · EX-99.1 to Form 8-K
Standard BioTools Reports Third Quarter 2025 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Standard BioTools Reports Second Quarter 2025 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Standard BioTools Enters Next Phase of Transformation
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Standard BioTools Reports First Quarter 2025 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Standard BioTools Reports Fourth Quarter and Full Year 2024 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Standard BioTools Announces Preliminary Fourth
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
business performance, including related to revenues, net loss and adjusted EBITDA, growth, margin and operating expenses; statements regarding future financial performance and expectations, operational and strategic plans, deployment of
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Standard BioTools Reports Third Quarter 2024 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Standard BioTools Reports Second Quarter 2024 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Standard BioTools Reports First Quarter 2024 Financial Results
Acquisition or disposition completed · Regulation FD disclosure · EX-99.1 to Form 8-K
Announces Operational Restructuring Plan to Drive Long-Term Profitable Growth
Exit or restructuring costs · Regulation FD disclosure · EX-99.1 to Form 8-K
Standard BioTools Announces Exchange of All
Material agreement · Unregistered share sale · Executive or director change · Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
Standard BioTools Reports Fourth Quarter and Full Year 2023 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Standard BioTools Announces Preliminary Fourth
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Leader in Life Sciences Tools
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Standard BioTools Stockholders Approve Merger
Acquisition or disposition completed · Executive or director change · Charter or bylaw amendment · Shareholder vote results · Other events · EX-99.1 to Form 8-K
Standard BioTools Completes Merger with SomaLogic,
Acquisition or disposition completed · Executive or director change · Charter or bylaw amendment · Shareholder vote results · Other events · EX-99.2 to Form 8-K
Glass Lewis Recommends Standard BioTools Stockholders
Other events · EX-99.1 to Form 8-K
ISS Recommends Standard BioTools Stockholders
Other events · EX-99.1 to Form 8-K
Investor Presentation Unlocking Value in a Fragmented Space DECEMBER 2023
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Hi {fname}! This is {agent_first_name} with Alliance Advisors,
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Meeting of Stockholder is fast approaching, and according to our records we have not received your vote.
Regulation FD disclosure · Other events · EX-99.3 to Form 8-K
Standard BioTools and SomaLogic Announce Date
Other events · EX-99.1 to Form 8-K
future financial performance and expectations, operational and strategic plans, deployment of capital, cash runway and sufficiency of cash resources, potential M&A activity, potential restructuring plans; and expectations with respect to the planned merger of Standard BioTools and SomaLogic,
Regulation FD disclosure · EX-99.1 to Form 8-K
Standard BioTools Reports Third Quarter and Year-to-Date 2023 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Standard BioTools and SomaLogic to Combine
Material agreement · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
O C T O B E R 4 , 2 0 2 3
Material agreement · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Voting Agreement (this “ Agreement ”), dated as of October 4, 2023, is by and among Standard BioTools Inc., a Delaware
Material agreement · Regulation FD disclosure · Other events · EX-99.3 to Form 8-K